Efti in Patients With Hormone Receptor Positive/HER2-neg Breast Cancer
Conditions
- Breast Cancer
- HER 2 Negative Breast Cancer
- HR Positive/HER-2 Negative Breast Cancer
- Stage 1-3
Interventions
- DRUG: Eftilagimod Alfa (Efti)
- DRUG: Docetaxel-cyclophosphamide (TC) intravenous (i.v)
- DRUG: Dose dense Adriamycin-cyclophosphamide (AC) i.v
Sponsor
George Washington University
Collaborators